{"id":"W2945221383","doi":"10.1038/s41416-019-0474-x","title":"A phase 2 trial of sunitinib in patients with progressive paraganglioma or pheochromocytoma: the SNIPP trial","year":2019,"lang":"en","type":"article","venue":"British Journal of Cancer","topic":"Adrenal and Paraganglionic Tumors","field":"Medicine","cited_by":122,"is_retracted":false,"has_abstract":true,"ca_institutions":"Foothills Medical Centre; Princess Margaret Cancer Centre; Centre Hospitalier de l’Université de Montréal; University Health Network","funders":"Pfizer Canada; Pfizer","keywords":"Paraganglioma; Sunitinib; SDHB; Medicine; Clinical endpoint; SDHA; Pheochromocytoma; Progressive disease; Internal medicine; Surgery; Metanephrines; Phases of clinical research; Oncology; Germline mutation; Randomized controlled trial; Chemotherapy; Cancer; Mutation","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003422451,0.0001258516,0.0005810721,0.0001131217,0.00003398052,0.00002360389,0.0001513652,0.00006252036,0.0008593765],"category_scores_gemma":[0.0001482476,0.00007428598,0.0001407349,0.0003741919,0.0001219626,0.0001355817,0.00001548081,0.0003479813,0.00000311301],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00006051736,"about_ca_system_score_gemma":0.0006809104,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00009148577,"about_ca_topic_score_gemma":0.0001281503,"domain_scores_codex":[0.9982418,0.0001102914,0.0006592351,0.0001263543,0.0006373269,0.0002249799],"domain_scores_gemma":[0.9984805,0.0001138573,0.0007477765,0.0001306537,0.0004209255,0.0001063009],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9427703,0.002755391,0.001395886,0.00006284966,0.0001942873,0.01571195,0.0002452241,0.000008503473,0.000007508913,0.000008912061,0.0005500338,0.03628916],"study_design_scores_gemma":[0.9457381,0.02314488,0.01706394,0.00222211,0.0002208263,0.009771897,0.0002033619,0.000008411259,0.000727836,0.00001848434,0.0007427457,0.0001373497],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9961543,0.001424984,0.000002449021,0.0001750581,0.0005158159,0.001397626,0.00004017664,0.000004735557,0.000284817],"genre_scores_gemma":[0.9988099,0.00003384369,0.00004020671,0.0001190277,0.0006928548,0.00002899541,0.000006571984,0.00001960115,0.000248979],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.03615181,"threshold_uncertainty_score":0.940957,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01418888539045209,"score_gpt":0.3169192574547395,"score_spread":0.3027303720642874,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}